Hong Kong-based chat management platform imBee has raised $5 million in a Series A round, while Tecon Pharmaceutical, a subsidiary of the Shenzhen-listed Tecon Biology, has secured $139 million to expand its manufacturing capabilities.
Register now to enjoy 3 free articles per month,
or log in to continue reading.
Stay informed with complimentary articles each month
Gain access to our exclusive newsletters delivered directly to your inbox
Be the first to know about all our summits!
Already a Subscriber? Log in
